Cargando…
Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains sca...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424860/ https://www.ncbi.nlm.nih.gov/pubmed/22919160 http://dx.doi.org/10.4103/0970-2113.99104 |
_version_ | 1782241274852540416 |
---|---|
author | Menon, Sarala Dharmshale, Sujata Chande, Chhaya Gohil, Aruna Lilani, Sunil Mohammad, Salim Joshi, Ameeta Chowdhary, Abhay Bharadwaj, Renu |
author_facet | Menon, Sarala Dharmshale, Sujata Chande, Chhaya Gohil, Aruna Lilani, Sunil Mohammad, Salim Joshi, Ameeta Chowdhary, Abhay Bharadwaj, Renu |
author_sort | Menon, Sarala |
collection | PubMed |
description | BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains scantier for India. In view of this, we reviewed our data over last five years. MATERIALS AND METHODS: Six hundred and seventy-three Mycobacterium tuberculosis isolates were subjected to drug susceptibility against primary anti-tuberculosis drugs by economic variant proportion method. All isolates resistant to isoniazid and rifampicin were taken as multi-drug resistant (MDR). RESULTS: Out of the 673 strains tested, 95 (14.11%) showed monoresistance, 365 (54.23%) strains were found to be resistant to more than one drug. A total of 118 (17.53%) strains were found to be resistant to all the four drugs tested. MDR was seen with 320 (47.54%) isolates. This study observed maximum resistance with rifampicin (74.4%) followed by streptomycin (70.0%), isoniazid (53.2%), and ethambutol (21.7%). CONCLUSION: While this information may not reflect true prevalence of drug resistance in the region, this may help in further planning long term surveillance studies to know the trend of drug resistance in this area. |
format | Online Article Text |
id | pubmed-3424860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-34248602012-08-23 Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study Menon, Sarala Dharmshale, Sujata Chande, Chhaya Gohil, Aruna Lilani, Sunil Mohammad, Salim Joshi, Ameeta Chowdhary, Abhay Bharadwaj, Renu Lung India Original Article BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains scantier for India. In view of this, we reviewed our data over last five years. MATERIALS AND METHODS: Six hundred and seventy-three Mycobacterium tuberculosis isolates were subjected to drug susceptibility against primary anti-tuberculosis drugs by economic variant proportion method. All isolates resistant to isoniazid and rifampicin were taken as multi-drug resistant (MDR). RESULTS: Out of the 673 strains tested, 95 (14.11%) showed monoresistance, 365 (54.23%) strains were found to be resistant to more than one drug. A total of 118 (17.53%) strains were found to be resistant to all the four drugs tested. MDR was seen with 320 (47.54%) isolates. This study observed maximum resistance with rifampicin (74.4%) followed by streptomycin (70.0%), isoniazid (53.2%), and ethambutol (21.7%). CONCLUSION: While this information may not reflect true prevalence of drug resistance in the region, this may help in further planning long term surveillance studies to know the trend of drug resistance in this area. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3424860/ /pubmed/22919160 http://dx.doi.org/10.4103/0970-2113.99104 Text en Copyright: © Lung India http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Menon, Sarala Dharmshale, Sujata Chande, Chhaya Gohil, Aruna Lilani, Sunil Mohammad, Salim Joshi, Ameeta Chowdhary, Abhay Bharadwaj, Renu Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title | Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title_full | Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title_fullStr | Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title_full_unstemmed | Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title_short | Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study |
title_sort | drug resistance profiles of mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: a five years study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424860/ https://www.ncbi.nlm.nih.gov/pubmed/22919160 http://dx.doi.org/10.4103/0970-2113.99104 |
work_keys_str_mv | AT menonsarala drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT dharmshalesujata drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT chandechhaya drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT gohilaruna drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT lilanisunil drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT mohammadsalim drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT joshiameeta drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT chowdharyabhay drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy AT bharadwajrenu drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy |